


## GW2580

**ALTERNATE NAME:** 5-(3-Methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine

**CATALOG #:** 1740-5, 25

**AMOUNT:** 5 mg, 25 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>20</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub>

**MOLECULAR WEIGHT:** 366.41

**CAS NUMBER:** 870483-87-7

**APPEARANCE:** Off-white solid

**SOLUBILITY:** DMSO (40 mg/ml)

**PURITY:** ≥99% by HPLC

**STORAGE:** Store at -20 °C

**DESCRIPTION:** A small-molecule, ATP-competitive inhibitor of cFMS kinase; at 60 nM it inhibits human cFMS kinase completely *in vitro* and was inactive against 26 other kinases. GW2580 also inhibits lipopolysaccharide (LPS)-induced TNF production in mice, but not LPS-induced TNF production in freshly isolated human monocytes and mouse macrophages *in vitro*.

**REFERENCE:** Conway, J.G., et al. (2005). *Proc. Natl., Acad. Sci. USA* **102**, 16078-16083.

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**FOR RESEARCH USE ONLY! Not to be used on humans.**

**RELATED PRODUCTS:**

- A 83-01 (Cat. No. 1725-1)
- ABT-869 (Cat. No. 1615-1,5)
- Axitinib (Cat. No. 1581-5, 25)
- BIBW2992 (Cat. No. 1616-1,5)
- BMS-599626 (Cat. No. 1614-1,5)
- Bosutinib (Cat. No. 1584-5, 25)
- Canertinib (Cat. No. 1617-5)
- Cediranib (Cat. No. 1613-1,5)
- CP-690550 (Cat. No. 1622-5,25)
- Dasatinib (Cat. No. 1586-25, 100)
- Erlotinib, Hydrochloride Salt (Cat. No. 1588-100,1000)
- Gefitinib (Cat. No. 1589-5,25)
- Genistein (Cat. No. 1533-10, 100)
- Imatinib Mesylate (Cat. No. 1625-100, 1000)
- Lapatinib Ditosylate (Cat. No. 1624-25,100)
- PD 153035, Hydrochloride (Cat. No. 1656-2)
- PD173074 (Cat. No. 1675-1)
- Saracatinib (Cat. No. 1582-5, 25)
- SB-431542 (Cat. No. 1674-1)
- Sorafenib (Cat. No. 1594-5, 25)
- SU-5402 (Cat. No. 1645-05)
- Sunitinib Malate (Cat. No. 1611-100, 1000)
- Tyrphostin AG 1295 (Cat. No. 1571-5)
- Tyrphostin AG 490 (Cat. No. 1570-5)